MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients

Stopped Felt not to show benefit over control per DMC and confirmed via futility analysis

Conditions

• Breast Cancer
• HER2 Positive Breast Cancer

Interventions

• DRUG: MM-302
• DRUG: Gemcitabine
• DRUG: Capecitabine
• DRUG: Vinorelbine
• DRUG: Trastuzumab

Sponsor

Merrimack Pharmaceuticals